QIAGEN and Neo4j Strengthen Partnership to Revolutionize Biomedical Data Analysis in Biopharma Industry

QIAGEN and Neo4j Strengthen Partnership to Revolutionize Biomedical Data Analysis in Biopharma Industry

(IN BRIEF) QIAGEN Digital Insights has announced an expanded partnership with Neo4j, aiming to enhance biomedical data analysis for the biopharmaceutical industry. This collaboration will integrate Neo4j’s graph database and machine learning capabilities with QIAGEN’s extensive biomedical knowledge base. By leveraging these technologies, the partnership seeks to uncover hidden insights in complex biological data, facilitating analytics-driven drug discovery and accelerating the development of new therapies. QIAGEN emphasizes its commitment to providing cutting-edge tools for biopharma companies, while Neo4j expresses confidence that their combined efforts will drive innovation and improve patient outcomes. The partnership will be showcased at BioTechX Europe 2024 in Basel, Switzerland.

(PRESS RELEASE) VENLO, 8-Oct-2024 — /EuropaWire/ — In a significant step forward for the biopharmaceutical industry, QIAGEN Digital Insights (QDI) has announced the expansion of its strategic partnership with Neo4j®, a leader in graph database technology and analytics. This collaboration aims to enhance the analysis of biomedical data, facilitating analytics-driven drug discovery and accelerating the development of new therapeutic solutions.

The new agreement will leverage QIAGEN’s extensive experience in biomedical data content curation, accumulated over 25 years, alongside Neo4j’s cutting-edge knowledge graph technologies and machine learning tools, including their innovative GraphRAG (Retrieval Augmented Generation) capabilities. This partnership is designed to help biopharma companies extract deeper insights from complex data sets, thereby streamlining the drug discovery process.

With a rich history in providing comprehensive biomedical knowledge through applications like QIAGEN Ingenuity Pathway Analysis and QIAGEN OmicSoft Lands, QDI’s commitment to delivering high-quality data solutions remains paramount. The integration with Neo4j’s graph database technology will allow QDI to uncover hidden patterns and relationships within biomedical data, empowering researchers to identify novel therapeutic targets more efficiently.

“Our collaboration with Neo4j has already yielded remarkable results in delivering insightful, graph-based analytics to our customers,” stated Dominic John, Vice President and Head of QIAGEN Digital Insights. “By deepening our partnership, we aim to enhance the functionality of our Biomedical Knowledge Base while exploring innovative methods and tools that will extend the capabilities of biomedical knowledge graphs. This initiative reflects our unwavering commitment to equipping biopharma companies with state-of-the-art tools to expedite their research and development efforts.”

Sudhir Hasbe, Chief Product Officer at Neo4j, expressed enthusiasm about the expanded partnership, stating, “We are excited to further our collaboration with QIAGEN Digital Insights, which has consistently led the way in applying graph technology within the life sciences sector. By refining and integrating with the QIAGEN biomedical knowledge graph, we anticipate unlocking new opportunities for biopharma companies, ultimately driving innovation and improving patient outcomes.”

The focus of this partnership will be on enhancing existing solutions and integrating new technologies that complement both companies’ biopharma portfolios. This strategic approach aims to ensure that biopharma customers have access to the latest tools for navigating and analyzing intricate biological data effectively.

For further details about this partnership and its implications for the biopharma sector, attendees can visit QIAGEN Digital Insights and Neo4j at BioTechX Europe 2024 in Basel, Switzerland (Neo4j stand #624; QIAGEN stand #328) or explore their websites for more information.

About QIAGEN Digital Insights
QIAGEN Digital Insights (QDI), the bioinformatics business of QIAGEN, is the leading provider of genomic and clinical knowledge, analysis and interpretation tools and services for scientists and clinicians. QDI has over 25 years of experience in the industry, 90,000 users worldwide, over 100,000 citations in scientific papers, more than 3 million profiled patient cases, and over 40 billion scientific data points. The portfolio includes expertly curated genomic and clinical knowledge solutions as well as bioinformatics software and services for efficient data management, sharing and actionable insights. Learn more at https://digitalinsights.qiagen.com/.

About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2024, QIAGEN employed more than 5,900 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

About Neo4j
Neo4j, the Graph Database & Analytics leader, helps organizations find hidden patterns and relationships across billions of data connections deeply, easily, and quickly. Customers leverage the structure of their connected data to reveal new ways of solving their most pressing business problems, from fraud detection, customer 360, knowledge graphs, supply chain, personalization, IoT, network management, and more – even as their data grows. Neo4j’s full graph stack delivers powerful native graph storage with native vector search capability, data science, advanced analytics, and visualization, with enterprise-grade security controls, scalable architecture, and ACID compliance. Neo4j’s dynamic open-source community brings together over 250,000 developers, data scientists, and architects across hundreds of Fortune 500 companies, government agencies, and NGOs. Visit neo4j.com.

Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Media Contacts:

Dr. Thomas Theuringer
Senior Director Corporate Communications & Head Of External Communications
Germany: +49 2103 29 11826
Mobile: +49 1520 18 11826
thomas.theuringer@qiagen.com

Lisa Specht
Manager Public Relations
Germany: +49 2103 29 14181
Mobile: +49 152 01811381
lisa.specht@qiagen.com

SOURCE: QIAGEN